GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Race Oncology Ltd (OTCPK:RAONF) » Definitions » Interest Coverage

Race Oncology (Race Oncology) Interest Coverage

: No Debt (1) (As of Dec. 2023)
View and export this data going back to 2020. Start your Free Trial

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Race Oncology's Operating Income for the six months ended in Dec. 2023 was $-6.78 Mil. Race Oncology's Interest Expense for the six months ended in Dec. 2023 was $0.00 Mil. Race Oncology has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Race Oncology Ltd has no debt.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Race Oncology's Interest Coverage or its related term are showing as below:

RAONF' s Interest Coverage Range Over the Past 10 Years
Min: No Debt   Med: No Debt   Max: No Debt
Current: No Debt


RAONF's Interest Coverage is ranked better than
99.15% of 355 companies
in the Biotechnology industry
Industry Median: 142.97 vs RAONF: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Race Oncology Interest Coverage Historical Data

The historical data trend for Race Oncology's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Race Oncology Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Interest Coverage
Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt No Debt

Race Oncology Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Interest Coverage Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt No Debt

Competitive Comparison

For the Biotechnology subindustry, Race Oncology's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Race Oncology Interest Coverage Distribution

For the Biotechnology industry and Healthcare sector, Race Oncology's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Race Oncology's Interest Coverage falls into.



Race Oncology Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Race Oncology's Interest Coverage for the fiscal year that ended in Jun. 2023 is calculated as

Here, for the fiscal year that ended in Jun. 2023, Race Oncology's Interest Expense was $0.00 Mil. Its Operating Income was $-9.16 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Race Oncology had no debt (1).

Race Oncology's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the six months ended in Dec. 2023, Race Oncology's Interest Expense was $0.00 Mil. Its Operating Income was $-6.78 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Race Oncology had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Race Oncology  (OTCPK:RAONF) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Race Oncology Interest Coverage Related Terms

Thank you for viewing the detailed overview of Race Oncology's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Race Oncology (Race Oncology) Business Description

Traded in Other Exchanges
Address
1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Race Oncology Ltd is a specialty pharmaceutical company. It is engaged in the development and marketing of pharmaceutical drugs for the treatment of Cancer. Its product includes Bisantrene, a cancer chemotherapy drug. Its operating segments include research into oncology drugs, Zantrene and the manufacturing and distribution of the drug for clinical trials.

Race Oncology (Race Oncology) Headlines